checkAd
    Startseite > Aktien > CytomX Therapeutics > Nachrichten
    CytomX Therapeutics
    Aktie
    ISIN: US23284F1057 WKN: A14158 SYM: 6C1 Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    1,2960
     
    EUR
    +0,15 %
    +0,0020 EUR
    Letzter Kurs 10:17:20 Tradegate
    Geldkurs
    10:54:45
    1,3000
     
    EUR
    3.000 STK
    Briefkurs
    10:54:45
    1,3230
     
    EUR
    1.134 STK

    CytomX Therapeutics Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
    22.05.24 · globenewswire · CytomX Therapeutics
    CytomX Therapeutics Announces New Employment Inducement Grants
    16.05.24 · globenewswire · CytomX Therapeutics
    CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    08.05.24 · globenewswire · CytomX Therapeutics
    CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY T-Cell Engager)
    08.05.24 · globenewswire · CytomX Therapeutics
    CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA (pembrolizumab)
    07.05.24 · globenewswire · CytomX Therapeutics
    Fokus Aktien mit extremen Handelsvolumen am Donnerstag, den 02.05.2024
    02.05.24 · wO Chartvergleich · Ansys
    CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch!
    02.05.24 · Sharedeals · CytomX Therapeutics
    CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
    01.05.24 · globenewswire · CytomX Therapeutics
    CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
    08.04.24 · globenewswire · CytomX Therapeutics
    CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
    03.04.24 · globenewswire · CytomX Therapeutics
    CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
    21.03.24 · globenewswire · CytomX Therapeutics
    CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
    18.03.24 · globenewswire · CytomX Therapeutics